2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Motor Activity
20
Polycystic Ovary Syndrome
10
Prostatic Neoplasms
7
Breast Neoplasms
6
Neoplasms
5
Colorectal Neoplasms
4
Insulin Resistance
3
Lung Neoplasms
2
Fatigue
2
Esophageal Neoplasms
2
Cardiotoxicity
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Primary Dysautonomias
1
Pediatric Brain Tumor
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Lymphoma, Follicular
1
Lupus Erythematosus, Systemic
1
Inflammation
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Disease
1
Diabetes Mellitus, Type 1
1
Chemotherapy-Related Cognitive Impairment
1
Cardiovascular Diseases
1
Interventions
Gemcitabine
157
Cisplatin
117
pembrolizumab
81
Cystectomy
46
Nivolumab
42
Carboplatin
42
Paclitaxel
41
Mitomycin
41
Docetaxel
39
atezolizumab
33
Magnetic Resonance Spectroscopy
33
Radiotherapy
31
durvalumab
30
avelumab
26
BCG Vaccine
26
Specimen Handling
25
Cystoscopy
24
enfortumab vedotin
23
Doxorubicin
23
Fluorouracil
20
Methotrexate
17
Vinblastine
16
Standard of Care
15
Ipilimumab
14
Filgrastim
14
5-aminolevulinic acid hexyl ester
14
Transurethral Resection of Bladder
13
Surgical Procedures, Operative
13
Sunitinib
13
Biopsy
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
High-Intensity Interval Training
×
Clear all
NCT04593862
2024-09-19
BRAVE
University of Alberta
Phase 2
Completed
25 enrolled